

December 25, 2013

Dainippon Sumitomo Pharma Co., Ltd.

Dainippon Sumitomo Pharma Sets Up the Oncology Clinical Development Unit

Osaka, Japan, December 25, 2013 – Dainippon Sumitomo Pharma Co., Ltd. (“DSP”) (Head Office: Osaka, Japan; President: Masayo Tada) today announced that it will set up the Oncology Clinical Development Unit, effective January 1, 2014.

DSP has set the Oncology area as the focus therapeutic area in addition to the Psychiatry & Neurology and channels all energies into innovative drug discovery. To serve this area of very high unmet medical needs, the Company has established an integrated global R&D system comprising the DSP Cancer Institute and Boston Biomedical, Inc., one of its key U.S. subsidiaries. The Oncology Clinical Development Unit is created as a unit specialized in the oncology area within the Company’s Drug Development Division with a view to strengthening oncology-related clinical development in Japan.

The new unit is designed to function strategically and with agility by having integrated in it all the mandates of clinical research, clinical operation and medical affairs for the oncology area in Japan. The Oncology Clinical Development Unit will be working very closely with Boston Biomedical, Inc. to accelerate the development activities in Japan and the launch of innovative products in the oncology area.

In a related move, the following personnel change will take place in key position on the same date.

New position (January 1, 2014)	Current position	Name
Director, Clinical Operation, Director, Oncology Clinical Development Unit	Director, Clinical Operation	Takashi Maniwa

Contact:
Corporate Communications
Dainippon Sumitomo Pharma Co., Ltd.
Telephone: +81-6-6203-1407 (Osaka), +81-3-5159-3300 (Tokyo)